Summary by Moomoo AI
Cingulate, Inc., a biopharmaceutical company, has filed a prospectus related to the resale of up to 6,630,000 shares of common stock, which may be issued upon the exercise of outstanding warrants. These warrants were initially issued to certain selling stockholders in a private placement that closed on July 1, 2024. The shares consist of 4,250,000 Series C Warrant Shares, 2,125,000 Series D Warrant Shares, and 255,000 Placement Agent Warrant Shares. The exercise prices for the Series C and D Warrants are $0.585 per share, while the Placement Agent Warrants have an exercise price of $0.7313. The warrants are exercisable following stockholder approval and will expire on the fifth and second anniversaries of the approval date for Series C and D Warrants, respectively. Cingulate will not receive proceeds from...Show More